PCR-ALERA: A PCR-ELISA analogue but antibody-free DNA detection system
Abstract
PCR-ALERA is a new concept for DNA detection that combines DNA amplification by polymerase chain reaction (PCR) with an activator-linked enzyme reactivation assay (ALERA). PCR-ALERA resembles the commercial, semi-quantitative PCR-ELISA assay that offers high sensitivity and high-throughput screening in microplates. PCR-ALERA overcomes a major drawback of PCR-ELISA since it does not require the time-consuming handling of expensive antibodies. In the first step of the assay, commercially available modified nucleotides were incorporated during PCR amplification of the target DNA. A selenocysteine containing peptide (the activator) was linked to the amplified DNA by click chemistry. This peptide has been optimized for the highly efficient activation of the latent protease papain by selenolate-triggered disulfide cleavage. The DNA-peptide hybrid was then immoblized in microplate wells and incubated with latent papain. The latter was readily activated and converted a fluorogenic substrate to a fluorescent product with high catalytic turnover. Overall assay time is about 4 hours including PCR.
Related
- Heterologous expression of the membrane protein OmpA from bovine Pasteurella multocida and establishment of an indirect ELISA for antibody detection
- A developed recombinant antigen and monoclonal antibody based solid phase competitive ELISA for detection of foot and mouth disease virus serotype O specific antibodies
- A dual recombinant strategy to quantify PreS1 antibody in hepatitis B patients with genotype B or C virus by ELISA
- MICA Allelic Variation Modulates Secretion and Protein Flexibility, Impacting on NKG2D‐Mediated Immune Responses and Antibody Detection
- Fusion-independent virus-like particles enable rapid detection of antibody-mediated inhibition of ligand-receptor interactions
BibTeX
@misc{bonenberger2026pcralera,
title = {{PCR-ALERA: A PCR-ELISA analogue but antibody-free DNA detection system}},
author = {Miles Bonenberger and Roland Krämer},
howpublished = {arXiv},
year = {2026},
month = oct,
doi = {10.48550/arxiv.2610.40262},
eprint = {2610.40262},
archivePrefix = {arXiv},
url = {https://arxiv.org/abs/2610.40262},
}
RIS
TY - UNPB
TI - PCR-ALERA: A PCR-ELISA analogue but antibody-free DNA detection system
AU - Miles Bonenberger
AU - Roland Krämer
PY - 2026
DA - 2026/10/29
PB - arXiv
DO - 10.48550/arxiv.2610.40262
UR - https://arxiv.org/abs/2610.40262
AB - PCR-ALERA is a new concept for DNA detection that combines DNA amplification by polymerase chain reaction (PCR) with an activator-linked enzyme reactivation assay (ALERA). PCR-ALERA resembles the commercial, semi-quantitative PCR-ELISA assay that offers high sensitivity and high-throughput screening in microplates. PCR-ALERA overcomes a major drawback of PCR-ELISA since it does not require the time-consuming handling of expensive antibodies. In the first step of the assay, commercially available modified nucleotides were incorporated during PCR amplification of the target DNA. A selenocysteine containing peptide (the activator) was linked to the amplified DNA by click chemistry. This peptide has been optimized for the highly efficient activation of the latent protease papain by selenolate-triggered disulfide cleavage. The DNA-peptide hybrid was then immoblized in microplate wells and incubated with latent papain. The latter was readily activated and converted a fluorogenic substrate to a fluorescent product with high catalytic turnover. Overall assay time is about 4 hours including PCR.
ER -